Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: J Clin Psychol Med Settings. 2020 Nov 21;28(3):603–618. doi: 10.1007/s10880-020-09750-4

Table 1.

Patient Sociodemographic and Treatment-related Characteristics (N=5)

Patient Characteristic Mean (SD) or Frequency (%)
Age (years) 57.5 (12.3)
Woman 5 (100%)
Race/ethnicity
 Non-Hispanic white 5 (100%)
Education
 2 years of college/AA/technical 4 (80%)
 College graduate 1 (20%)
Annual household income
 $50,000-$99,999 3 (60%)
 $100,000 or greater 2 (40%)
Current relationship status
 Married or living with someone else 5 (100%)
Menopausal Status
 Post-menopausal 4 (80%)
Breast cancer stage
 Stage 0 1 (20%)
 Stage IA 1 (20%)
 Stage IIA 2 (40%)
 Stage IIB 1 (20%)
Type of adjuvant endocrine therapy
 Letrozole 2 (40%)
 Exemestane 1 (20%)
 Anastrozole 1 (20%)
 Tamoxifen 1 (20%)
Months since initiating adjuvant endocrine therapy (median; range) 5 (1–12)
Type of primary breast cancer treatment
 Surgery only 2 (40%)
 Surgery & Chemotherapy 1 (20%)
 Surgery & Radiation 1 (20%)
 Surgery, Chemotherapy, & Radiation 1 (20%)
Baseline Adherence Rate (Electronic Medical Event Monitoring System [MEMS Caps]) 82.86% (38.33)
*

Note: SD = Standard Deviation